HomeHealthcare & Life SciencesPharmaceuticals Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market

Global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Size & Outlook, 2026-2034


Global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Insights

  • Based on Reed Intelligence findings, the Global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market reached USD 185 Million in 2025 and is estimated to attain USD 414.33 Million by 2034.
  • From 2026 to 2034, the Global market is expected to grow at a steady CAGR of 9.3%.
  • Within the Treatment Type category, Drug Therapy dominated in 2025 in terms of market size contribution.
  • Over the forecast period, Gene Therapy is forecasted to deliver the fastest growth, positioning it as the most lucrative Treatment Type segment.

Other Key Findings


  • United States is projected to lead the global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market size by 2034.
  • Across Global, North America is anticipated to hold the dominant position in market size by 2034.
  • North America is forecasted to expand at the fastest pace in Global, attaining USD 129.75 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 185 Million
Market Size In 2034 USD 414.33 Million
Largest segment Drug Therapy
Units Revenue in USD Million
CAGR 9.3% (2026-2034)
Segmnetation Covered
Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Middle East and Africa
  5. LATAM
Treatment Type
  1. Drug Therapy
  2. Gene Therapy
  3. Supportive Therapy
Route of Administration
  1. Oral
  2. Injectable
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Homecare Settings
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports